preDiCT

Many drugs fail to reach the market because of side effects on the heart. The principal objective of this proposal is to create an advanced computational technology for in silico assessment of the efficacy and safety of specific drugs [ICT-2007.5.3(c) (3)], i.e. an open environment comprising validated computational models, tools and numerical methods that will enable simulations of drug actions on the electrophysiology of the human heart.

Such simulations will involve modelling of drug interactions at the molecular and cellular level, will extend current technology to enable prediction of the effects of those interactions on the dynamics of the whole heart, and will lead to an understanding of how genetic factors can be used to assess patient-specific risk profiles. This requires a multi-level systems approach, based on multi-scale, multi-physics methods, including computations on adaptive spatial grids and multi-grid time integration. Computations on realistic models at appropriate spatial and temporal scales are currently not feasible, so we will investigate new algorithms and their implementation on high-performance platforms, including a new generation of petaflop computers, to achieve 'faster than real-time' simulation.

These tools form part of the infrastructure required to simulate the physiology of major organ systems, thereby contributing to the goal of creating the Virtual Physiological Human (VPH) [ICT-2007.5.3]. The balanced team in this project, including founders of the Human Physiome Project, has decades of experience in the experimental study and modelling of the electrophysiology and mechanics of the heart, while pharmaceutical industry partners bring deep understanding of the mechanisms of drug actions. The results will demonstrate the value of the VPH initiative to fundamental scientific understanding of the heart, with major economic and clinical impacts through accelerated drug development, approval and use.

For further information, please visit:
http://www.vph-predict.eu

Project co-ordinator:
The Chancellor, Master and Scholars of the University of Oxford

Partners:

  • F. Hoffmann-La Roche AG
  • Szegedi Tudományegyetem
  • Fujitsu Laboratories of Europe Limited
  • Glaxo Smithkline Research and Development
  • Universidad Politécnica de Valencia
  • Centro di Ricerca, Sviluppo e Studi Superiori in Sardegna
  • Novartis Pharma AG
  • Aureus Pharma SA

Timetable: from 06/2008 – to 05/2011

Total cost: € 5.545.692

EC funding: € 4.100.000

Programme Acronym: FP7-ICT

Subprogramme Area: Virtual physiological human

Contract type: Collaborative project (generic)


Related news article:

Most Popular Now

Open Medical Works with Moray's Dig…

Open Medical is working with the Digital Health & Care Innovation Centre’s Rural Centre of Excellence on a referral management plan, as part of a research and development scheme to...

Generative AI on Track to Shape the Futu…

Using advanced artificial intelligence (AI), researchers have developed a novel method to make drug development faster and more efficient. In a new paper, Xia Ning, lead author of the study and...

AI could Help Improve Early Detection of…

A new study led by investigators at the UCLA Health Jonsson Comprehensive Cancer Center suggests that artificial intelligence (AI) could help detect interval breast cancers - those that develop between...

Reorganisation, Consolidation, and Cuts:…

NHS England has been downsized and abolished. Integrated care boards have been told to change function, consolidate, and deliver savings. Trusts are planning big cuts. The Highland Marketing advisory board...

AI-Human Task-Sharing could Cut Mammogra…

The most effective way to harness the power of artificial intelligence (AI) when screening for breast cancer may be through collaboration with human radiologists - not by wholesale replacing them...

AI Tool Uses Face Photos to Estimate Bio…

Eyes may be the window to the soul, but a person's biological age could be reflected in their facial characteristics. Investigators from Mass General Brigham developed a deep learning algorithm...

Siemens Healthineers infection Control S…

Klinikum Region Hannover (KRH) has commissioned Siemens Healthineers to install infection control system (ICS) at the Klinikum Siloah hospital. The ICS aims to effectively tackle nosocomial infections and increase patient...

Philips Future Health Index 2025 Report …

Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today unveiled its 2025 Future Health Index U.S. report, "Building trust in healthcare AI," spotlighting the state of...

AI-Powered Precision: Unlocking the Futu…

A team of researchers from the Department of Diagnostic and Therapeutic Ultrasonography at the Tianjin Medical University Cancer Institute & Hospital, have published a review in Cancer Biology & Medicine...

AI Model Improves Delirium Prediction, L…

An artificial intelligence (AI) model improved outcomes in hospitalized patients by quadrupling the rate of detection and treatment of delirium. The model identifies patients at high risk for delirium and...

SALSA: A New AI Tool for the Automated a…

Investigators of the Vall d'Hebron Institute of Oncology's (VHIO) Radiomics Group, led by Raquel Perez-Lopez, have developed SALSA (System for Automatic Liver tumor Segmentation And detection), a fully automated deep...

Call for Papers: AI Applications in Biom…

JMIR Biomedical Engineering is inviting submissions for a new section titled "AI Applications in Biomedical Engineering." This themed section explores the integration of biomedical engineering and artificial intelligence (AI), focusing...